A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).
Ritu SalaniMary McCormackYong-Man KimSharad GhamandeShaundra L HallDomenica LorussoLisa BarracloughLucy GilbertAdrian Guzman RamirezChien-Hsing LuRenaud SabatierNicoletta ColomboYouyou HuVenkatesh KrishnanLuciana MolineroYuning FengNicole KimMarcela CastroYvonne G LinBradley J MonkPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
The objective response rate with the tiragolumab-plus-atezolizumab combination was numerically higher than the historical reference but did not reach statistical significance.